Cure My Disease

Don't miss your cure!

 Log in / Sign up

How long do HPV vaccine antibodies last? a 11-Year Follow-Up aims to find out

NCT ID NCT07820241

Prevention Sponsor: Shanghai Zerun Biotechnology Co.,Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 15, 2026 · Last updated Sep 18, 2026 · Updated 3 times

Summary

Researchers are tracking HPV-16 and HPV-18 neutralizing antibodies in females who received a bivalent HPV vaccine in an earlier study. Participants were 9 to 26 years old when first vaccinated and received either two or three doses. No vaccine is given in this extension. Blood samples are collected at months 84, 108, and 132 after the first dose to measure antibody levels and see how many women remain above the threshold for protection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bivalent human papillomavirus vaccine (types 16 and 18)
What this could lead to
If antibody levels stay high for years, this could support fewer booster doses and simpler HPV vaccination schedules. It may also reassure people that two doses work as well as three for younger girls.
What could go wrong
This study only measures antibodies in blood, not whether vaccinated people actually avoid HPV infection or cervical cancer. Antibody levels can drop over time, and a low level does not always mean lost protection. The results may not apply to males or to other HPV vaccines.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

348 people

The number who actually took part.

Started

Mar 2023

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Females previously enrolled in study 311-HPV-1004 (NCT02740777) at the Hezhou and Zhongshan study sites in Guangxi, China, who completed the required blood-collection visits in the base study and met the eligibility criteria for the extension study.

Ages

16 to 34 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The participant, and the participant's legal guardian when applicable, is able to understand the study information and voluntarily sign the informed consent form for the extension study. * In the investigator's judgment, the participant is able to comply with protocol requirements, including attending scheduled visits and responding to follow-up telephone contacts. * The participant was enrolled in study 311-HPV-1004 and completed blood collection at Day 0 and Months 7, 12, 24, and 36. Exclusion Criteria: * Receipt of any HPV vaccine other than the study vaccine during study 311-HPV-1004 or between completion of that study and enrollment in this extension study. * Use of an investigational or unregistered product, other than the study vaccine, during study 311-HPV-1004 or between completion of that study and enrollment in this extension study. * Seropositivity for both HPV-16 and HPV-18 antibodies at baseline in study 311-HPV-1004. * Long-term use of immunosuppressive agents or

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Human papillomavirus infection are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

human papilloma virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Human papillomavirus infection

Contacts and locations

Locations

  • Hezhou Center for Disease Control and Prevention

    Hezhou, Guangxi, China

  • Zhongshan County Center for Disease Control and Prevention

    Hezhou, Guangxi, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.